NRX Pharmaceuticals (NRXP) EBITDA Margin (2025 - 2026)

NRX Pharmaceuticals' (NRXP) quarterly EBITDA Margin came in at 444.01% in Q1 2026, up 8.01% on a QoQ basis from 482.67% in Q4 2025.

NRX Pharmaceuticals (NRXP) EBITDA Margin (2025 - 2026) Analysis & Trends

NRX Pharmaceuticals (NRXP) has 2 years of EBITDA Margin data on file, last reported at 444.01% in Q1 2026.

On a quarterly basis, EBITDA Margin changed N/A year-over-year to 444.01% in Q1 2026; TTM through Mar 2026 was 769.09%, a N/A change from a year earlier, with the FY2025 full-year figure at 1352.0%, changed N/A from the prior year.
EBITDA Margin for Q1 2026 stood at 444.01%, up from 482.67% in the prior quarter.
Over the last five years, EBITDA Margin for NRXP reached as high as 444.01% in Q1 2026 and fell as low as 2012.0% in Q3 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	EBITDA Margin (Qtr)
1	Oculis Holding AG	67,222.41 Bn	67,222.13 Bn	-	-
2	Nanobiotix	1,909.44 Bn	1,909.38 Bn	-	-
3	Akari Therapeutics	989.71 Bn	989.71 Bn	-	-
4	BeOne Medicines	472.06 Bn	467.27 Bn	1.35 Bn	16.51%
5	Vertex Pharmaceuticals	122.10 Bn	114.85 Bn	2.59 Bn	38.10%
6	Regeneron Pharmaceuticals	70.00 Bn	61.25 Bn	3.31 Bn	17.83%
7	Belite Bio	62.68 Bn	62.68 Bn	-	-
8	Argenx Se	55.75 Bn	50.57 Bn	1.41 Bn	31.68%
9	Alnylam Pharmaceuticals	37.50 Bn	34.50 Bn	959.66 Mn	23.02%
10	NRX Pharmaceuticals	116.33 Mn	109.63 Mn	437,000.00	-444.01%

Download Data